S&P Futures
3,991.25 +8.25 (+0.21%) Dow Futures
32,519.00 +63.00 (+0.19%) Nasdaq Futures
12,701.00 +12.50 (+0.10%) Russell 2000 Futures
1,769.40 +8.70 (+0.49%) Crude Oil
67.29 -0.35 (-0.52%) Gold
1,983.60 +0.80 (+0.04%)
Design Therapeutics, Inc. (DSGN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.48 |
| Open | 6.53 |
| Bid | 6.54 x 800 |
| Ask | 8.50 x 800 |
| Day's Range | 6.49 - 6.72 |
| 52 Week Range | 6.08 - 26.30 |
| Volume | |
| Avg. Volume | 479,784 |
| Market Cap | 364.534M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.60 |
- GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year Continued Progress Across Pipeline of GeneTAC™ Small Molecules with Three Programs Expected to be in Clinical Development in the Next Two Years Strong Financial Position with $330 Million in Cash and Securities Expected to Support Operating Runway through 2025 CARLSBAD, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company
- GlobeNewswire
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
CARLSBAD, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference on Wednesday, February 15, 2023, at 5:00 p.m. ET. A live webcast will be available in the investor section of the company's
- Simply Wall St.
Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)
Investors who take an interest in Design Therapeutics, Inc. ( NASDAQ:DSGN ) should definitely note that the Independent...
